Vi­a­tris launch­es gener­ic for As­traZeneca's asth­ma and COPD drug Sym­bi­cort

As­traZeneca’s block­buster asth­ma and COPD drug Sym­bi­cort, which brought in $2.5 bil­lion for the phar­ma gi­ant in 2022, now has a gener­ics com­peti­tor from Vi­a­tris.

Vi­a­tris teamed up with Kinde­va Drug De­liv­ery to launch its own in­halant Brey­na, a com­plex drug-de­vice com­bo that marks the first out­side gener­ic to come to mar­ket to com­pete with Sym­bi­cort, Vi­a­tris an­nounced Mon­day. As­traZeneca launched an au­tho­rized gener­ic in Jan­u­ary 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER